Dr. M. Tyrrell Burrus, Leading Orthopedic Surgeon in Austin, Introduces Advanced Surgical Techniques for Shoulder, Knee, and Ankle Care
Austin, TX – Dr. M. Tyrrell Burrus, a trusted name in orthopedic surgery in Austin, is proud to announce the integration of cutting-edge technologies and advanced surgical techniques into his practice. As a renowned shoulder surgeon in Austin, Dr. Burrus is committed to providing his patients with the latest, most effective treatments available to ensure faster recovery and improved outcomes. With the addition of innovative shoulder and knee procedures, Dr. Burrus continues to lead the way in orthopedic care.
Shoulder Replacements with Advanced Templating Technology
In an effort to offer the best possible outcomes for patients requiring shoulder replacement surgery, Dr. Burrus now utilizes the Arthrex Virtual Implant Positioning™ (VIP) System for precise and accurate shoulder surgery. This advanced templating software allows for optimal placement of the shoulder implant, improving alignment, reducing surgical time, and enhancing recovery for patients. As a trusted shoulder doctor Austin, Dr. Burrus is dedicated to utilizing the most advanced tools available to improve patient satisfaction and long-term results.
ACL Reconstruction with Quadriceps Tendon Autograft
Dr. Burrus is now offering ACL reconstruction surgery using quadriceps tendon autograft, a minimally invasive technique that is transforming ACL repair. The QuadPro™ tendon harvester, provided by Arthrex, is designed to harvest a quadriceps or patellar tendon graft with precision and minimal disruption to surrounding tissue. This technique enhances recovery time and reduces the risk of complications, making it an ideal choice for patients looking for a safer, more effective ACL reconstruction option. As a leading knee surgeon Austin, Dr. Burrus employs this innovative technology to address knee injuries with the utmost care and precision.
ACL Surgery with Internal Brace Backup Fixation
For those undergoing ACL reconstruction, Dr. Burrus offers the Arthrex ACL Backup Fixation System, which provides enhanced tibial fixation to ensure the strength and stability of the graft during healing. This system includes a SwiveLock® implant and a spade-tipped drill, allowing for strong, reproducible fixation that is critical for successful outcomes. The InternalBrace™ ligament augmentation technology further strengthens the repaired ACL, making it ideal for patients with high activity levels. Dr. Burrus, a leading knee specialist Austin, is proud to offer this advanced solution to patients seeking comprehensive ACL repair options.
MPFL Reconstruction for Patellar Instability
For patients experiencing patellar instability, Dr. Burrus now offers the Arthrex MPFL Reconstruction procedure, utilizing an anatomic double-bundle technique to replicate the natural shape of the medial patellofemoral ligament (MPFL). This technique provides stability in both flexion and extension, helping to prevent rotational instability throughout the range of motion. As a trusted knee doctor Austin, Dr. Burrus provides effective solutions for patients struggling with patellar instability, allowing them to return to normal activity levels with improved confidence and mobility.
Comprehensive Ankle Care
In addition to his expertise in shoulder and knee care, Dr. Burrus also offers comprehensive ankle surgery services in Austin. As a highly experienced ankle surgeon Austin, he provides personalized treatment plans for patients dealing with a variety of ankle injuries and conditions. From fractures to chronic instability, Dr. Burrus offers advanced surgical options to help patients regain mobility and improve their quality of life.
About Dr. M. Tyrrell Burrus, MD
Dr. M. Tyrrell Burrus is an experienced orthopedic surgeon specializing in shoulder, knee, and ankle surgery in Austin, TX. With a commitment to providing state-of-the-art care and personalized treatment plans, Dr. Burrus helps his patients achieve the best possible outcomes. His use of the latest technologies and techniques ensures that patients receive the highest quality of care in a compassionate and professional environment.
For more information on Dr. Burrus's services or to schedule a consultation, please visit his website at https://drtyrrellburrus.com/ or contact his office at (512) 324-9170.
Contact Information
Dr. M. Tyrrell Burrus, MD
Website: https://drtyrrellburrus.com/
Phone: (512) 324-9170
Source: https://thenewsfront.com/dr-m-tyrrell-burrus-leading-orthopedic-surgeon-in-austin-introduces-advanced-surgical-techniques-for-shoulder-knee-and-ankle-care/
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare
Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13, 2025 /PRNewswire/ -- The Berwyn Group (Berwyn), the leader in death audit, locate services and population management, is pleased to announce the hiring of Adam Wilson as General Manager of Healthcare. Wilson brings extensive healthcare industry experience that will further strengthen Berwyn's commitment to excellence and growth. Berwyn offers an end-to-end suite of industry-leading death audit and locate solutions that enable pension and health plan administrators to eliminate costly overpayments, maximize efficiency, meet regulatory requirements, and connect policyholders, participants and beneficiaries to the funds they deserve. More than 2,000 corporate, union and government clients use Berwyn's flagship services, CertiDeath® and CertiCensus®. Wilson joins Berwyn with a distinguished career that spans almost 17 years at UnitedHealthcare, where he held several leadership roles including Vice President of Workforce Planning, Chief of Staff to the COO, and Vice President of Medicare Part D products. "We are thrilled to welcome Adam to the team," said John Bikus, President of Berwyn. "His strategy, proven leadership, and deep industry knowledge will be invaluable as we continue to grow in the healthcare industry." In his new role, Wilson will be responsible for leading Berwyn's strategic expansion into the healthcare market. He will be focusing on aligning Berwyn's solutions to the healthcare payer and provider business cycle needs while also extending the Berwyn reach to healthcare-related supporting partners, vendors, and industry trade groups. "I'm eager to join an organization positioned for rapid growth through industry-leading capabilities," said Wilson. "I look forward to collaborating with the talented team at Berwyn to deliver quick wins, strategic expansion into healthcare, and contribute to the company's continued success." About The Berwyn Group The Berwyn Group is the leader in population data management, offering the industry's most trusted and effective death audit and locate solutions, with an unmatched dedication to innovation, security, and generating outcomes. Acquired by Longevity Holdings in 2023, The Berwyn Group offers an end-to-end suite of industry-leading solutions including CertiDeath® Paragon™, CertiDeath®, CertiCensus®, CertiSearch® and BeneSearch®. Connecting leading-edge technology and data with best-in-class human ingenuity, Berwyn helps bridge the gap between pensions and their participants, insurance companies and their policyholders, third-party administrators and public entities with Medicaid recipients. For more information, visit Media Contact Karlene Gilmore Director of Marketing kgilmore@ View original content: SOURCE The Berwyn Group, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Vitamin gummies sold at ALDI and BJ's nationwide recalled
(WHTM) — Several vitamin gummy supplements that were sold at ALDI and BJ's stores nationwide have been recalled. According to the U.S. Food & Drug Administration (FDA), Vita Warehouse Corp. has voluntarily recalled one lot of Welby® brand Vitamin B12 Energy Support gummy product (1000 mcg 140 gummies), Berkely Jensen® Vitamin B12 (1000 mcg 250 Gummies), and VitaGlobe™ Vitamin B12 Extra Strength (60 Gummies). Close Thanks for signing up! Watch for us in your inbox. Subscribe Now These vitamins were recalled because of the potential presence of undeclared peanuts. To date, no illnesses or allergic reactions have been reported. The FDA says this recall was initiated after ALDI conducted routine testing as part of their standard protocol to verify accuracy of allergen-related claims on product labeling. One test result indicated the potential presence of a peanut allergen. It should be noted that Vita Warehouse Corp. verified the absence of peanuts in the product, but the recall is being initiated out of an abundance of caution. According to the FDA, the recalled products were distributed at ALDI and BJ's stores nationwide and online at and The only products that are included in this recalled are: Product UPC Code Lot # Expiration Date Aldi Welby 4099100290868 248046601 10/2026 Berkley Jensen 888670132487 248046601 10/2026 VitaGlobe 850005214670 248046601 10/2026 Moving forward, consumers who are allergic to peanuts and have purchase the recalled products are urged to return them to the place of purchase for a full refund, or discard of them immediately. If you have any questions, you can contact the company at 1-855-214-0100 or email Vita Warehouse at info@ abc27 news will keep you updated as more information becomes available. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
